BioPharma Dive November 10, 2023
Cleared for adults 18 and older in the U.S., the preventive shot will be sold as Ixchiq.
The Food and Drug Administration on Thursday cleared drugmaker Valneva’s preventive chikungunya virus vaccine in adults, the first shot to prevent illness from the mosquito-borne disease.
The vaccine, which will be sold as Ixchiq, is approved for U.S. adults 18 years and older who are at increased risk of exposure to the chikungunya virus.
“The first-ever licensed chikungunya vaccine will play a crucial role in preventing the suffering caused by this debilitating disease,” said Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations, in a statement provided by Valneva. “Climate change is intensifying the threat posed by chikungunya, which means safe and...
Today's Sponsors
Today's Sponsor